Strs Ohio Has $892,000 Stake in Twist Bioscience Co. (NASDAQ:TWST)

Strs Ohio cut its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 13.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 24,200 shares of the company’s stock after selling 3,700 shares during the period. Strs Ohio’s holdings in Twist Bioscience were worth $892,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TWST. Charles Schwab Investment Management Inc. boosted its position in Twist Bioscience by 3.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock worth $8,965,000 after purchasing an additional 14,511 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Twist Bioscience by 559.5% during the third quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company’s stock worth $2,159,000 after acquiring an additional 90,413 shares in the last quarter. Dark Forest Capital Management LP lifted its holdings in shares of Twist Bioscience by 121.3% in the third quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company’s stock worth $597,000 after acquiring an additional 16,142 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $451,000. Finally, Citigroup Inc. boosted its stake in shares of Twist Bioscience by 94.1% in the 3rd quarter. Citigroup Inc. now owns 264,204 shares of the company’s stock valued at $5,353,000 after purchasing an additional 128,098 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on TWST shares. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and increased their price objective for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th. Barclays dropped their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Finally, Scotiabank boosted their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the sale, the chief executive officer now owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the sale, the director now directly owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the transaction, the chief executive officer now owns 516,409 shares in the company, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. Insiders have sold a total of 11,037 shares of company stock worth $384,092 over the last quarter. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Trading Down 2.4 %

NASDAQ:TWST opened at $30.75 on Thursday. Twist Bioscience Co. has a one year low of $11.46 and a one year high of $43.21. The firm’s 50 day simple moving average is $35.15 and its 200 day simple moving average is $30.32.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The company had revenue of $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. During the same period last year, the company earned ($0.74) earnings per share. The firm’s revenue was up 31.8% compared to the same quarter last year. As a group, sell-side analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.